Segui
Janet Dancey
Janet Dancey
Canadian Cancer Trials Group/Queen's University
Email verificata su ctg.queensu.ca
Titolo
Citata da
Citata da
Anno
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, ...
European journal of cancer 45 (2), 228-247, 2009
277352009
Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd, J Dancey, R Ramlau, K Mattson, R Gralla, M O’Rourke, ...
Journal of Clinical Oncology 41 (15), 2673-2681, 2023
28612023
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ...
The Lancet Oncology 18 (3), e143-e152, 2017
19202017
RECIST 1.1—Update and clarification: From the RECIST committee
LH Schwartz, S Litière, E De Vries, R Ford, S Gwyther, S Mandrekar, ...
European journal of cancer 62, 132-137, 2016
14562016
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich, DA Reardon, T Peery, JM Dowell, JA Quinn, KL Penne, ...
Journal of Clinical Oncology 22 (1), 133-142, 2004
8692004
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ...
Journal of Clinical Oncology 23 (23), 5294-5304, 2005
8332005
Response assessment criteria for brain metastases: proposal from the RANO group
NU Lin, EQ Lee, H Aoyama, IJ Barani, DP Barboriak, BG Baumert, ...
The lancet oncology 16 (6), e270-e278, 2015
8142015
Issues and progress with protein kinase inhibitors for cancer treatment
J Dancey, EA Sausville
Nature reviews Drug discovery 2 (4), 296-313, 2003
8032003
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang, P Wen, T Cloughesy, H Greenberg, D Schiff, C Conrad, K Fink, ...
Investigational new drugs 23, 357-361, 2005
4722005
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of …
MJ Moore, J Hamm, J Dancey, PD Eisenberg, M Dagenais, A Fields, ...
Journal of clinical oncology 21 (17), 3296-3302, 2003
4682003
mTOR signaling and drug development in cancer
J Dancey
Nature reviews Clinical oncology 7 (4), 209-219, 2010
4412010
Strategies for optimizing combinations of molecularly targeted anticancer agents
JE Dancey, HX Chen
Nature reviews Drug discovery 5 (8), 649-659, 2006
4342006
The genetic basis for cancer treatment decisions
JE Dancey, PL Bedard, N Onetto, TJ Hudson
Cell 148 (3), 409-420, 2012
4102012
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
MB Thomas, R Chadha, K Glover, X Wang, J Morris, T Brown, A Rashid, ...
Cancer 110 (5), 1059-1067, 2007
4102007
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
KS Saini, S Loi, E de Azambuja, O Metzger-Filho, ML Saini, M Ignatiadis, ...
Cancer treatment reviews 39 (8), 935-946, 2013
4072013
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group
AM Oza, L Elit, MS Tsao, S Kamel-Reid, J Biagi, DM Provencher, ...
Journal of Clinical Oncology 29 (24), 3278, 2011
3822011
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
I Duran, J Kortmansky, D Singh, H Hirte, W Kocha, G Goss, L Le, A Oza, ...
British journal of cancer 95 (9), 1148-1154, 2006
3792006
Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres
JE Dancey, FA Shepherd, K Paul, KW Sniderman, S Houle, J Gabrys, ...
Journal of nuclear medicine 41 (10), 1673-1681, 2000
3602000
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
JJ Raizer, LE Abrey, AB Lassman, SM Chang, KR Lamborn, JG Kuhn, ...
Neuro-oncology 12 (1), 95-103, 2010
3322010
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
RK Ramanathan, CP Belani, DA Singh, M Tanaka, HJ Lenz, Y Yen, ...
Cancer chemotherapy and pharmacology 64, 777-783, 2009
3292009
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20